Introduction {#Sec1}
============

A placebo is defined as an inert or nonactive treatment, that is, a substance or treatment of no intended therapeutic value \[[@CR1]\]. The term comes from the Latin verb "to please." Common placebos include inert tablets such as sugar pills, inert injections such as saline, sham therapies, or sham surgery \[[@CR2]\].

Placebos are usually employed in clinical trials to control for nonspecific effects but have been found to cause clinically relevant changes and, in some cases, be indistinguishable from the treatment against which they are tested \[[@CR3]\]. They are used to help researchers to determine the effectiveness of a drug or treatment. In this way, treatments that are usually considered effective and even used as standard of care can be challenged \[[@CR4]\]. The first placebo-controlled trial is believed to have been conducted in 1799 \[[@CR5]\]. When a person who is taking the inactive substance or who has had a sham treatment reports that symptoms have improved, this improvement is called the placebo effect.

There are multiple possible components of a measured placebo effect. Some of them depend on the patient, such as the past effect of active treatments, physiological mediators (expectations, desires, and emotions), brain structures involved in reward/aversion and regulation of emotions, endogenous opioids or endocannabinoids \[[@CR6]\], or classical conditioning. Other factors influencing the placebo effect depend on the physician, such as empathy or cues that signal that an active treatment has been given, or depend on the type of treatment.

A significant amount of research has been carried out in the field of pain and analgesia, and the placebo analgesic response appears to be the best-understood model of placebo mechanisms. However, other placebo responses result from less conscious processes, such as classical conditioning in the case of immune, hormonal, and respiratory functions \[[@CR5]\].

Various published studies comparing placebo or sham therapies with treatments in neuropathic pain, especially in carpal tunnel syndrome (CTS), are available. Some recent studies compared neurodynamic techniques, platelet-rich plasma ultrasound-guided injection, low-level laser therapy, minocycline, topical chamomile oil, radial shock wave therapy, oscillatory biofield therapy, acetyl-[l]{.smallcaps}-carnitine (ALCAR), gabapentin, and topical menthol with placebo or sham therapies for treatment of mild and moderate CTS.

Giving a placebo to a patient when there is an effective treatment available is a bioethically complex issue. Informed consent is usually required for a study to be considered ethical, including the disclosure that some test subjects will receive placebo treatment. The ethics of placebo-controlled studies were debated in the revision process of the Declaration of Helsinki \[[@CR5]\].

The aim of the present study is to draw attention to the placebo effect and quantify it in the conservative treatment of CTS.

Materials and methods {#Sec2}
=====================

A double-blinded randomized study was conducted with 68 patients with a diagnosis of mild to moderate CTS divided into two groups receiving either palmitoylethanolamide (PEA) or placebo during 60 days. The study was approved by the ethics committee of our institution. Exclusion criteria were history of previous upper extremity surgery, active treatment with steroids, use of night splinting, or food allergies. Patients selected for the study had to be between 18 and 75 years of age and suffer from mild or moderate CTS for at least 3 months with an electromyographical study (EMG) to confirm the diagnosis. Patients were asked to sign an informed consent form to be included in this study. Before and 2 months after treatment, a clinical and electromyographical study (EMG) were conducted, registering pain on a visual analogue scale (VAS), presence of Durkan, Tinel, and Phalen's signs, and the Levine questionnaire. Levine's questionnaire, which includes a symptom severity score (SSS) and a functional score (FSS), was conducted in a Spanish translation before and after the treatment.

Group N included the patients receiving 600 mg PEA, while patients in group P received placebo pills that looked exactly the same for 60 days. Thereafter, another EMG and clinical study including the Levine questionnaire were performed, recording any complications that the patient might refer. Two patients (one in each group) did not complete the treatment for causes unrelated to the medication, and five more did not have a follow-up EMG due to refusal or loss of the report. The 61 patients with full reports included 18 females and 12 males in group N, and 19 females and 12 males in group P. The right hand was affected in 39 patients, and the left one in 25. Fibromyalgia was diagnosed in three patients in group N but not in group P. The results regarding treatment with PEA have already been published \[[@CR7]\], and the present report focuses on the placebo effect in the treatment of mild and moderate CTS.

Data were analyzed using the R project statistical package \[[@CR8]\] with a *p*-value of \> 0.05. The *t*-test was used for data following a normal distribution, and the Wilcoxon rank-sum test with continuity correction was used for quantitative data. Presence or absence of clinical signs were assessed statistically using the chi-squared test. The *t*-test was used to search for statistically significant changes in the values of VAS, Levine's questionnaire, and EMG.

Results {#Sec3}
=======

The average age in group P was 53.32 years (SD 13.43) with an average weight of 72.43 kg (SD 13.03) and BMI of 28.85 kg/m^2^ (SD 4.84). No complications due to the use of placebo were recorded. The recorded values of the studied parameters are presented in Table [1](#Tab1){ref-type="table"}. Note that, in this table, all subjective parameters improved, although only SSS and the total Levine score reached a statistically significant level.Table 1Average parameters before and after treatment (SD in brackets) with their variationPretreatmentPosttreatmentDifference*p*-Value*t*-ValueVAS4.06 (3.42)3.25 (3.18)−0.8 (3.08)0.15541.4572FSS2.24 (0.66)1.96 (0.77)−0.27 (0.87)0.086561.772SSS2.57 (0.74)2.11 (0.81)−0.45 (0.78)0.002809\*3.255Levine questionnaire2.4092.04−0.3680.01251\*2.657Sensitive speed40.53 (7.05)42 (8.54)2.13 (9.08)0.262−1.15Sensitive peak amplitude8.86 (5.42)11.12 (6.13)1.198 (5.22)0.2625−1.1476Motor latency3.87 (0.91)3.71 (0.7)−0.057 (0.41)0.53450.632\*Statistically significant data

Discussion {#Sec4}
==========

The magnitude of the placebo effect is very difficult to assess due to the many factors involved (Table [2](#Tab2){ref-type="table"}). Studies that quantify the placebo effect show very different values depending on the condition treated and each of the items being measured. In low back pain, for example, the reduction of pain measured by VAS showed a reduction that ranged from 29% for maximum pain to 46% for minimum pain, while back pain-related disability decreased by 40% and pain bothersomeness decreased by 34% \[[@CR9]\]. In a metaanalysis on knee osteoarthritis, placebo treatment produced a 22--27% VAS reduction and 28--29% improvement in WOMAC score \[[@CR10]\]; and in a CTS study, placebo showed a reduction in night discomfort of 7.7%, swelling of 11.5%, movement discomfort of 13%, and poor coordination of 5.2% \[[@CR11]\]. In a study of CTS treated with neurodynamic techniques, the placebo group showed a 2.9% reduction in VAS. Amanzio \[[@CR12]\] studied the placebo effect versus analgesics and showed differences in pain intensity of 1--1.5 out of 10 units in a VAS attributable to the placebo effect. These improvements in pain intensity can reach 5 units out of 10 in patients considered as placebo responders \[[@CR13]\].Table 2Factors involved in the placebo effectPatient and environment or psychosocial determinants of the placebo effectPathology involvedMeasured itemPast effect of active treatmentsPsychological mediators (expectations, desires, and emotions)Brain structures involved in reward/aversion and regulation of emotionsEndogenous opioidsClassical conditioningPhysicianCues that signal that an active treatment has been givenEmpathyType of treatmentType of administrationLook of the product

In the present study, the measured improvement of CTS with placebo in patient-dependent items ranged from 12.05% for FSS and 17.51% for SSS to 19.7% for VAS; And in objective items, such as those measured by EMG, the improvement was 1.47% for motor latency, 5.26% for sensitive speed, and 13.52% for sensitive peak amplitude. These results imply a spontaneous improvement of CTS in our patients during the period of study, which would add to the improvement due to the placebo effect.

Psychological factors that influence the placebo effect include classical conditioning, past experiences of the patient, especially those involving the use of active treatments, but also expectations, desires, and emotions.

The placebo effect also has a neuroanatomic basis that has been proven in magnetic resonance imaging (MRI) studies. Endogenous opioids have also shown to be involved in the placebo effect. Levine showed in 1978 \[[@CR14]\] that analgesia provided by placebo could be antagonized by naloxone, indicating mediation by endogenous opioid systems. Furthermore, several neurobiologists have shown that the placebo effect reduces neural activity in brain areas related to anxiety and pain and increases that in areas involved in emotional regulation \[[@CR15]\]. Thus, placebo produces a real biological effect that would not preclude its use in medical practice on the grounds of ethical reasons. However, we are aware that these issues can be difficult to deal with in the clinical setting, especially when explaining our treatment plan to the patient and their family. Telling the patient and their family that we are using a placebo is bound to make it disappear, but on the other hand, it would be unethical to give the patient a medication about which they are not informed. Curiously enough, this vision is not supported by an article by Kaptchuk et al. \[[@CR16]\] that showed persistence of the placebo effect in spite of the patient knowing about it. This is a highly controversial topic, but many physicians use placebo in their practice \[[@CR17]\].

Physicians' attitudes towards the patient and their communicating skills also influence the placebo effect, with both active treatments and placebo. The way the physician communicates can sometimes give inadvertent cues that, in a clinical trial, the product prescribed is the active one: not only by the act of prescription, but also through a global attitude that can instill confidence, empathy, and reassurance, and so to say, prepare the brain for pain control \[[@CR18]\]. Conditioning, verbal suggestions, and behaviors manifested by healthcare providers can determine placebo responses, as demonstrated in studies that used open instead of hidden administration of a drug, for example, using a computer-programmed drug infusion pump \[[@CR12], [@CR19]--[@CR21]\].

The type of treatment used also has an effect on the final result. Thus, it is well known that more aggressive treatments are seen as more effective \[[@CR22]\], so intravenous medication will be seen as more effective than oral medication by the patient \[[@CR23]\]. Even the color of the administered substance contributes to the placebo effect; Also, when surgery is an option, it is also seen as more effective than conservative treatment \[[@CR4]\].

One of the weaknesses of this study is that the results cannot be split between a group of placebo responders and another of nonresponders. The results should therefore be interpreted as those from a general population.

In the present study, pain measured by VAS should rather be considered a measure of bothersomeness, since the main problem in the condition studied is paresthesia and not pain itself.

As we have seen, several factors influence the placebo effect. Subtle differences in these factors can have a huge impact on the measured response to a treatment, which could explain the variability in the measured outcomes of placebo studies. Therefore, the relative contribution of each of these factors remains to be established. In the clinical setting, care providers can ethically take advantage of this placebo effect to enhance the effectiveness of treatments with proven results \[[@CR24]\].
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